Last week, a number stealthily moved through the group of endocrinologists and diabetes researchers in a Milan conference hall, seemingly surprising almost everyone. Twenty-three percent. When taking the highest dosage of Eli Lilly’s experimental combination therapy, which combines the already potent Mounjaro ingredient tirzepatide with an experimental substance called eloralintide, participants lost that much body weight on average. The figure felt almost overwhelming to a field that had spent years celebrating double-digit percentage losses as a ceiling.
The information is from a 48-week Phase 2b study that included 367 adults with type 2 diabetes and obesity, a group that has traditionally rejected even the most intensive weight-loss programs. Starting from a baseline of about 232 pounds, people on that peak combination dose lost an average of 54.1 pounds. For comparison, patients taking 15 mg of tirzepatide alone—a dose that is already regarded as potent by modern standards—lost roughly 34.4 pounds. The distinction is not insignificant. It weighs almost twenty pounds.
The reasoning behind this combination is what makes it intriguing and possibly more resilient than the standard pharmaceutical headline. GLP-1 and GIP, two gut hormones that indicate fullness and control blood sugar, are already mimicked by tirzepatide. By focusing on amylin, a hormone secreted by the pancreas along with insulin that slows digestion and signals to the brain that a meal is finished, eloralintide creates a third pathway. The idea at Lilly seems to be to engage three hormone systems more gently rather than exerting more pressure on any one of them. The head of Lilly’s cardiometabolic division, Ken Custer, characterized it as “lightly engaging three hormone systems rather than blasting any one of them.” It’s a catchphrase, in part because it seems almost paradoxical coming from a company whose current products are already some of the strongest metabolic agents available.
Some analysts believe that this trial presents EloraTZP as a direct competitor to Novo Nordisk’s CagriSema, which also combines GLP-1 targeting agents with amylin. Although it’s still unclear if that comparison will hold up in the end—Phase 3 data will be crucial—the competitive framing has undoubtedly inspired investors. The market potential for eloralintide, according to Leerink Partners analyst David Risinger, is far greater than Wall Street had realized, especially for patients who either couldn’t tolerate current GLP-1 medications or just didn’t react as they had hoped. It turns out that there are millions of people in that group.
However, it would be too simple to interpret this narrative as wholly victorious. With dropout rates from side effects ranging from 10.8% to 27%, depending on the dose, more patients stopped the combination therapy than tirzepatide alone. These are numbers that require sincere consideration. Patients most commonly experience nausea, vomiting, and general gastrointestinal distress during the dose escalation phase, which is typical for this class of medications but still a real barrier for those attempting to continue treatment long enough to see results. Lilly quickly points out that in its early Phase 2 work in 2018, high-dose tirzepatide itself displayed similar discontinuation patterns, and they are preparing a revised escalation schedule for Phase 3. A slower ramp-up might significantly alter the tolerability picture.
There was also a significant change in blood sugar regulation. A1C, a long-term indicator of glucose control, was lowered by up to 2.9% with the combination as opposed to 2.4% with tirzepatide alone. That distinction can result in actual clinical outcomes for a person with type 2 diabetes, such as a lower risk of problems affecting the kidneys, eyes, and cardiovascular system. In other words, even though everyone keeps quoting the scale numbers, the drug isn’t just about the scale.
It’s difficult to ignore the direction that obesity medicine appears to be taking. GLP-1 medications seemed like a real breakthrough a few years ago. The question of whether single-hormone approaches are even the proper framework has now come up. Phase 3 will take time, and co-formulated injections combining both agents are still being developed, so the Mounjaro eloralintide weight loss study data does not provide a definitive answer to that question. However, the path seems worth carefully pursuing for patients who have gone through treatments that didn’t work well enough, as well as for doctors who witness those patients’ struggles. Phase 3 starts before the year is out, according to Lilly. When the results are received, they will be carefully examined.
FAQs
Q1: How much weight did participants lose on the highest dose of EloraTZP?
An average of 54.1 pounds, or 23.3% of body weight, over 48 weeks.
Q2: How does eloralintide differ from tirzepatide?
It targets amylin, a third hormone pathway that tirzepatide alone doesn’t address.
Q3: What were the most common side effects of the combination therapy?
Gastrointestinal issues, generally mild to moderate, mainly during dose escalation.
Q4: When will EloraTZP Phase 3 trials begin?
Eli Lilly plans to initiate Phase 3 studies before the end of 2026.
Q5: Who was this trial designed for?
Adults with obesity or overweight who also have type 2 diabetes.
